Controlling for drug dose in systematic review and meta-analysis: A case study of the effect of antidepressant dose

Medical Decision Making

Volumn 29, Issue 1, 2009, Pages 91-103

  Hansen, Richard A ^a   Moore, Charity G ^b   Dusetzina, Stacie B ^a   Leinwand, Brian I ^a   Gartlehner, Gerald ^c   Gaynes, Bradley N ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DANUBE UNIVERSITY KREMS   (Austria)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Comparative effectiveness; Dose; Dose response; Meta analysis; Meta regression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CASE STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DESCRIPTIVE RESEARCH; DOSE RESPONSE; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EFFECT SIZE; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; META ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 59549086791     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08323298     Document Type: Article

References (23)

1. Clancy C. AHRQ's Research Efforts in Comparative Effectiveness. Statement before the U.S. House of Representatives Subcommittee on Health Committee on Ways and Means. Rockville, MD: Agency for Healthcare Research and Quality. June 12, 2007. Available from: URL: http://www.ahrq.gov/news/sp061207.htm
2. Cook DJ, Mulrow CD, Haynes RB Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997 ; 126 (5). 376-80.
3. Institute of Medicine. Learning what works best: the nations need for evidence on comparative effectiveness in health care. September 2007. Available from: URL: http://www.iom.edu/ebm-effectiveness
4. Lau J., Ioannidis JP, Schmid CH Quantitative synthesis in systematic reviews. Ann Intern Med. 1997 ; 127 (9). 820-6.
5. Bousquet J., Ben-Joseph R., Messonnier M., Alemao E., Gould AL A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002 ; 24 (1). 1-20.
6. Kelly HW Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003 ; 91 (4). 326-34 ; quiz 334-5, 404.
7. Zhang J., Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 ; 296 (13). 1619-32.
8. Bongartz T., Sutton AJ, Sweeting MJ, Buchan I., Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 ; 295 (19). 2275-85.
9. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-73.
10. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-59.
11. Bech P., Tanghoj P., Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002 ; 163 (1). 20-5.
12. Monteleone P., Gnocchi G. Evidence for a linear relationship between plasma trazodone levels and clinical response in depression in the elderly. Clin Neuropharmacol. 1990 ; 13 (Suppl 1). S84-9.
13. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demi-track MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004 ; 14 (6). 457-70.
14. Pritchett YL, Marciniak MD, Corey-Lisle PK, Berzon RA, Desaiah D., Detke MJ Use of effect size to determine optimal dose of duloxetine in major depressive disorder. J Psychiatr Res. 2007 ; 41 (3-4). 311-8.
15. Hansen RA, Gartlehner G., Lohr KN, Gaynes BN, Carey TS Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005 ; 143 (6). 415-26.
16. Gartlehner G., Hansen RA, Thieda P., et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative Effectiveness Review No. 7. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available from: www.effectivehealthcare.ahrq.gov/reports/ final.cfm
17. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 2002 ; 21 (11). 1539-58.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-60.
19. Davis JM, Chen N., Glick ID A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 ; 60 (6). 553-64.
20. Bollini P., Pampallona S., Tibaldi G., Kupelnick B., Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry. 1999 ; 174: 297-303.
21. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004 ; 24 (2). 192-208.
22. Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry. 2007 ; 190: 287-92.
23. Ruhe HG, Huyser J., Swinkels JA, Schene AH Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry. 2006 ; 189: 309-16.